Zachary A. Zimmerman
Founder at Forge Therapeutics, Inc.
Profile
Zachary A.
Zimmerman is the founder of Forge Therapeutics, Inc., Blacksmith Medicines, Inc. Prior to founding these companies, he worked as the Director of Business Development at Alnylam Pharmaceuticals, Inc., Senior Director of Development at Regulus Therapeutics, Inc., and Chief Business Officer at Arcturus Therapeutics, Inc. Zimmerman holds a doctorate degree from the University of California, Santa Cruz.
Zachary A. Zimmerman active positions
| Companies | Position | Start |
|---|---|---|
Forge Therapeutics, Inc.
 Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | Founder | - |
Blacksmith Medicines, Inc.
 Blacksmith Medicines, Inc. Pharmaceuticals: MajorHealth Technology Blacksmith Medicines, Inc. is a pharmaceutical company based in San Diego, CA and has subsidiaries in the United States. Blacksmith Medicines is focused on developing medicines that target metal-dependent enzymes found in human physiology. The company's platform combines a focused library of metal-binding pharmacophores with proprietary computational modeling approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzymes active site. The company recognized a large unmet need for new chemical matter and innovative approaches to drug this important class of enzymes. The company was founded by Zachary A. Zimmerman and has been led by him as the CEO since incorporation. | Chief Executive Officer | - |
Former positions of Zachary A. Zimmerman
| Companies | Position | End |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| REGULUS THERAPEUTICS INC. | Corporate Officer/Principal | - |
Arcturus Therapeutics, Inc.
 Arcturus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcturus Therapeutics, Inc. engages in the development of technology and therapeutics for rare diseases. It specializes in the application of application of ribonucleic acid technologies for the treatment of disease. The company was founded by Joseph E. Payne and Padmanabh Chivukula in 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Training of Zachary A. Zimmerman
| University of California, Santa Cruz | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| REGULUS THERAPEUTICS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Arcturus Therapeutics, Inc.
Arcturus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcturus Therapeutics, Inc. engages in the development of technology and therapeutics for rare diseases. It specializes in the application of application of ribonucleic acid technologies for the treatment of disease. The company was founded by Joseph E. Payne and Padmanabh Chivukula in 2013 and is headquartered in San Diego, CA. | Health Technology |
Forge Therapeutics, Inc.
Forge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA. | Health Technology |
Blacksmith Medicines, Inc.
Blacksmith Medicines, Inc. Pharmaceuticals: MajorHealth Technology Blacksmith Medicines, Inc. is a pharmaceutical company based in San Diego, CA and has subsidiaries in the United States. Blacksmith Medicines is focused on developing medicines that target metal-dependent enzymes found in human physiology. The company's platform combines a focused library of metal-binding pharmacophores with proprietary computational modeling approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzymes active site. The company recognized a large unmet need for new chemical matter and innovative approaches to drug this important class of enzymes. The company was founded by Zachary A. Zimmerman and has been led by him as the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Zachary A. Zimmerman
